UK markets closed

AN2 Therapeutics, Inc. (ANTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.2500+0.0300 (+0.93%)
At close: 04:00PM EDT
3.3300 +0.08 (+2.46%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.2200
Open3.2300
Bid3.2400 x 200
Ask3.2800 x 100
Day's range3.2300 - 3.3800
52-week range2.7200 - 22.2200
Volume400,756
Avg. volume419,091
Market cap96.66M
Beta (5Y monthly)-0.26
PE ratio (TTM)N/A
EPS (TTM)-2.8000
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est20.00
  • Business Wire

    AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

    MENLO PARK, Calif., March 28, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023.

  • Insider Monkey

    13 Best Falling Stocks To Buy Right Now

    In this piece, we will take a look at the 13 best falling stocks to buy now. If you want to skip our coverage of the latest stock market news, then you can take a look at the 5 Best Falling Stocks To Buy Right Now. The start of the year has seen some stocks […]

  • Reuters

    UPDATE 1-AN2 Therapeutics to pause lung disease study enrollment

    AN2 Therapeutics said on Monday it will pause further enrollment in a mid-to-late-stage study testing its experimental drug to treat a type of bacterial lung infection, citing potentially lower-than-expected efficacy. The company was conducting a mid-stage study testing epetraborole, a once-daily oral drug to treat MAC lung disease, caused by bacterial infection. AN2 said the decision to pause enrollment will give time to further evaluate the study data and it expects to announce top-line results from the study in the summer.